Here is the design of a clinical trial:

Official Title: Does a Simplified Algorithm and Integrated HCV Care Improve Linkage to Care, Retention, and Cure Among People Who Inject Drugs? A Pragmatic Quality Improvement Randomized Controlled Trial

Included conditions:
- Hepatitis C

Study Armgroups:
- {'label': 'Usual Care within Community Clinics', 'type': 'NO_INTERVENTION', 'description': "Complete blood count, comprehensive metabolic panel, international normalized ratio, HCV RNA, hepatitis B virus (HBV) serologies, point of care HIV test, and point of care liver fibrosis measurement. HCV genotype if required by patient's insurance for prior authorization. Care for opioid use disorder and skin infection is offered. Completion of the initial visit workup is sufficient to initiate a prior authorization request for DAAs from payers and an appointment for MAT follow-up in a community clinic if indicated. Patient coordination; authorization with insurance companies; scheduling appointments, follow-up, and ancillary support services will be conducted by a Patient Navigator. Patients are seen every 2-4 weeks for monitoring and adherence support. HCV treatment regimens are at the discretion of the treating provider in accordance with AASLD/IDSA guidelines and insurance requirements. Twelve weeks after HCV therapy completion, SVR12 HCV RNA and SVR12 CMP tests will be obtained."}
- {'label': 'Simplified Care within a Mobile Medical Unit', 'type': 'EXPERIMENTAL', 'description': 'Simplified Care treatment is the same as for Usual Care with the exception that it is taking place within a mobile medical clinic that is scheduled to deliver treatment in alignment with regular syringe exchange services.', 'interventionNames': ['Other: Simplified HCV care within a mobile medical unit']}

Interventions:
- {'type': 'OTHER', 'name': 'Simplified HCV care within a mobile medical unit', 'description': 'Delivers guideline-based care for HCV in a stream-lined manner on a mobile medical unit', 'armGroupLabels': ['Simplified Care within a Mobile Medical Unit']}

Primary Outcomes:
- {'measure': 'Number of patients who initiate HCV treatment', 'description': 'Initiating treatment with a Direct-Acting Antiviral (DAA)', 'timeFrame': '6 months of follow-up'}

Please estimate the sample size based on the assumption: 
Two-sided, two-sample proportion test with 80% power at a significance level of 5%.
Sample size justification
        To ensure that the proposed study has adequate power to determine the effectiveness of the simplified algorithm to determine the effectiveness of the simplified algorithm to improve HCV treatment initiation, i.e., the percentage of patients who are HCV RNA positivie and initiate treatment, the sample size was calculated based on a two-sided, two-sample proportion test with 80% power at a significance level of 5%. According to existing FHCSD data, between 20-25% of HCV infected patients (HCV RNA positive) initiate care [20]. Because the proposed treatment strategy addresses both barriers and facilitators of HCV treatment initiation, we believe that a greater than 15-20% improvement in care initiation is achievable. Thus, when the proportion of patients who initiate treatment in the control group is 20%, the target sample of approximately 200 patients (100 per study group) will provide sufficient power to detect a difference of approximately 17.5%. Furthermore, existing FHCSD data indicates that in the syringe exchange setting, approximately 15-20% of patients who take a rapid finger stick test are HCV Ab positive and of those, roughly 75% are HCV RNA positive [21]. Therefore, we will aim to administer approximately 1,350 tests during patient recruitment in order to identify approximately 200 patients who are HCV RNA positive and will be offered treatment.